Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 2/20 | 0.48 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NPY2R | P49146 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4695183 | 0.90 | PRCP (0.52) | PRCPCARM1PRMT6BACE1KDM4E | |
| SCHEMBL14282940 | 0.88 | ALDH1A1 (0.52) | PRCPKDM4EALDH1A1NPY2R | |
| SCHEMBL4072745 | 0.86 | PRCP (0.49) | PRCPCARM1PRMT6BACE1KDM4E | |
| SCHEMBL12123733 | 0.85 | PRCP (0.55) | PRCPCARM1PRMT6BACE1KDM4E | |
| SCHEMBL14282941 | 0.85 | PRCP (0.54) | PRCPCARM1PRMT6BACE1KDM4E | |
| SCHEMBL4071991 | 0.82 | CHRM2 (0.59) | — | |
| SCHEMBL7280203 | 0.80 | SLC18A3 (0.51) | PRCPCARM1PRMT6BACE1ALDH1A1 | |
| SCHEMBL28442705 | 0.80 | SIGMAR1 (0.66) | PRCPSMN1; SMN2CARM1PRMT6ALDH1A1 | |
| SCHEMBL14282906 | 0.80 | PRCP (0.44) | PRCPCARM1PRMT6BACE1NPY2R | |
| SCHEMBL14198387 | 0.78 | DRD2 (0.60) | CARM1PRMT6BACE1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1742707-A4 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-7355042-B2 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1443929-A4 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION INC (US) | 2008-02-06 | — | — | EP | disclosed |
| US-7317026-B2 | Sleep disorders; side effect reduction ; antihistamine antagonist | HYPNION, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-7189757-B2 | Treatment of sleep disorders using CNS target modulators | HYPNION, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1742707-A2 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | Hypnion, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005103041-A9 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION INC (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005103041-A2 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION, INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| US-20050080265-A1 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. | 2005-04-14 | — | — | US | disclosed |
| US-20050009730-A1 | Treatment of cns disorders using cns target modulators | HYPNION, INC. | 2005-01-13 | — | — | US | disclosed |
| EP-1443929-A2 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | Hypnion, Inc. (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040142972-A1 | CNS target modulators | HYPNION, INC. | 2004-07-22 | — | — | US | disclosed |
| US-20030187021-A1 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2003032912-A2 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION, INC. (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009730-A1 | Treatment of cns disorders using cns target modulators | HCRTR2, CNR2, CNR1 | PRCP 1192/4885SMN1; SMN2 370/4885CARM1 822/4885 |
| US-20030187021-A1 | Treatment of CNS disorders using CNS target modulators | HCRTR2, CNR2, CNR1 | PRCP 1192/4885SMN1; SMN2 370/4885CARM1 822/4885 |
| US-20050080265-A1 | Treatment of CNS disorders using CNS target modulators | HCRTR2, HRH3, HCRTR1 | PRCP 1324/4885SMN1; SMN2 902/4885CARM1 1004/4885 |
| US-20040142972-A1 | CNS target modulators | HCRTR2, CNR2, CNR1 | PRCP 1715/4885SMN1; SMN2 957/4885CARM1 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.